EREG

References

Title

Authors

Source

Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family

Toyoda H., Komurasaki T., Uchida D., Morimoto S.,

Biochem. J. 326:69-75(1997)

Complete sequencing and characterization of 21,243 full-length human cDNAs

Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Sugano S.,

Nat. Genet. 36:40-45(2004)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4

Komurasaki T., Toyoda H., Uchida D., Morimoto S.,

Oncogene 15:2841-2848(1997)

Solution structure of epiregulin and the effect of its C-terminal domain for receptor binding affinity

Sato K., Nakamura T., Mizuguchi M., Miura K., Tada M., Aizawa T., Gomi T., Miyamoto K., Kawano K.,

FEBS Lett. 553:232-238(2003)

Epiregulin: roles in normal physiology and cancer

Riese D.J. II, Cullum R.L.,

Semin. Cell Dev. Biol. 28:49-56(2014)

The consensus coding sequences of human breast and colorectal cancers

Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Velculescu V.E.,

Science 314:268-274(2006)

Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family.

Toyoda H., Komurasaki T., Uchida D., Morimoto S.,

Biochem. J. 326:69-75(1997)

Complete sequencing and characterization of 21,243 full-length human cDNAs.

Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Sugano S.,

Nat. Genet. 36:40-45(2004)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.

Komurasaki T., Toyoda H., Uchida D., Morimoto S.,

Oncogene 15:2841-2848(1997)

Solution structure of epiregulin and the effect of its C-terminal domain for receptor binding affinity.

Sato K., Nakamura T., Mizuguchi M., Miura K., Tada M., Aizawa T., Gomi T., Miyamoto K., Kawano K.,

FEBS Lett. 553:232-238(2003)

Epiregulin: roles in normal physiology and cancer.

Riese D.J. II, Cullum R.L.,

Semin. Cell Dev. Biol. 28:49-56(2014)

The consensus coding sequences of human breast and colorectal cancers.

Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Velculescu V.E.,

Science 314:268-274(2006)

Shc and FAK differentially regulate cell motility and directionality modulated by PTEN.

Gu J., Tamura M., Pankov R., Danen E.H., Takino T., Matsumoto K., Yamada K.M.,

J Cell Biol 146:389-403(1999)

The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase.

Joazeiro C.A., Wing S.S., Huang H.-K., Leverson J.D., Hunter T., Liu Y.-C.,

Science 286:309-312(1999)

Essential role of phosphoinositide metabolism in synaptic vesicle recycling.

Cremona O., Di Paolo G., Wenk M.R., Luthi A., Kim W.T., Takei K., Daniell L., Nemoto Y., Shears S.B., Flavell R.A., McCormick D.A., De Camilli P.,

Cell 99:179-188(1999)

The SH3 domains of endophilin and amphiphysin bind to the proline-rich region of synaptojanin 1 at distinct sites that display an unconventional binding specificity.

Cestra G., Castagnoli L., Dente L., Minenkova O., Petrelli A., Migone N., Hoffmueller U., Schneider-Mergener J., Cesareni G.,

J. Biol. Chem. 274:32001-32007(1999)

Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis.

Takei K., Slepnev V.I., Haucke V., De Camilli P.,

Nat Cell Biol 1:33-39(1999)

Phosphatidylinositol-3-OH kinases are Rab5 effectors.

Christoforidis S., Miaczynska M., Ashman K., Wilm M., Zhao L., Yip S.C., Waterfield M.D., Backer J.M., Zerial M.,

Nat Cell Biol 1:249-252(1999)

The epsins define a family of proteins that interact with components of the clathrin coat and contain a new protein module.

Rosenthal J.A., Chen H., Slepnev V.I., Pellegrini L., Salcini A.E., Di Fiore P.P., De Camilli P.,

J. Biol. Chem. 274:33959-33965(1999)

Phospholipase C-gamma as a signal-transducing element.

Carpenter G., Ji Q.,

Exp Cell Res 253:15-24(1999)

Role of cyclin G-associated kinase in uncoating clathrin-coated vesicles from non-neuronal cells.

Greener T., Zhao X., Nojima H., Eisenberg E., Greene L.E.,

J. Biol. Chem. 275:1365-1370(2000)

A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling.

Rodrigues G.A., Falasca M., Zhang Z., Ong S.H., Schlessinger J.,

Mol Cell Biol 20:1448-1459(2000)

Mapping of Eps15 domains involved in its targeting to clathrin-coated pits.

Benmerah A., Poupon V., Cerf-Bensussan N., Dautry-Varsat A.,

J Biol Chem 275:3288-3295(2000)

A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis.

Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E., Klagsbrun M., Elenius K.,

J. Biol. Chem. 275:8641-8649(2000)

Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis.

Gual P., Giordano S., Williams T.A., Rocchi S., Van Obberghen E., Comoglio P.M.,

Oncogene 19:1509-1518(2000)

Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4.

Rio C., Buxbaum J.D., Peschon J.J., Corfas G.,

J. Biol. Chem. 275:10379-10387(2000)

The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles.

Domin J., Gaidarov I., Smith M.E.K., Keen J.H., Waterfield M.D.,

J. Biol. Chem. 275:11943-11950(2000)

FAK integrates growth-factor and integrin signals to promote cell migration.

Sieg D.J., Hauck C.R., Ilic D., Klingbeil C.K., Schaefer E., Damsky C.H., Schlaepfer D.D.,

Nat. Cell Biol. 2:249-256(2000)

Ligand discrimination in signaling through an ErbB4 receptor homodimer.

Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C., Carraway K.L. III,

J. Biol. Chem. 275:19803-19807(2000)

ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor.

Borg J.-P., Marchetto S., Le Bivic A., Ollendorff V., Jaulin-Bastard F., Saito H., Fournier E., Adelaide J., Margolis B., Birnbaum D.,

Nat. Cell Biol. 2:407-414(2000)

Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis.

Confalonieri S., Salcini A.E., Puri C., Tacchetti C., Di Fiore P.P.,

J. Cell Biol. 150:905-912(2000)

Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.

Xu W., Mimnaugh E., Rosser M.F., Nicchitta C., Marcu M., Yarden Y., Neckers L.,

J Biol Chem 276:3702-3708(2001)

All three PACSIN isoforms bind to endocytic proteins and inhibit endocytosis.

Modregger J., Ritter B., Witter B., Paulsson M., Plomann M.,

J. Cell Sci. 113:4511-4521(2000)

Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1.

Duan R., Xie W., Burghardt R.C., Safe S.,

J Biol Chem 276:11590-11598(2001)

Clathrin uncoating: Auxilin comes to life.

Lemmon S.K.,

Curr Biol 11:R49-52(2001)

The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking.

Gaidarov I., Smith M.E.K., Domin J., Keen J.H.,

Mol. Cell 7:443-449(2001)

Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2.

Cunnick J.M., Mei L., Doupnik C.A., Wu J.,

J Biol Chem 276:24380-24387(2001)

Multiple interactions of auxilin 1 with clathrin and the AP-2 adaptor complex.

Scheele U., Kalthoff C., Ungewickell E.,

J Biol Chem 276:36131-36138(2001)

HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2.

Metzler M., Legendre-Guillemin V., Gan L., Chopra V., Kwok A., McPherson P.S., Hayden M.R.,

J. Biol. Chem. 276:39271-39276(2001)

The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis.

Waelter S., Scherzinger E., Hasenbank R., Nordhoff E., Lurz R., Goehler H., Gauss C., Sathasivam K., Bates G.P., Lehrach H., Wanker E.E.,

Hum. Mol. Genet. 10:1807-1817(2001)

Clathrin- and AP-2-binding sites in HIP1 uncover a general assembly role for endocytic accessory proteins.

Mishra S.K., Agostinelli N.R., Brett T.J., Mizukami I., Ross T.S., Traub L.M.,

J. Biol. Chem. 276:46230-46236(2001)

Unique phosphorylation mechanism of Gab1 using PI 3-kinase as an adaptor protein.

Onishi-Haraikawa Y., Funaki M., Gotoh N., Shibuya M., Inukai K., Katagiri H., Fukushima Y., Anai M., Ogihara T., Sakoda H., Ono H., Kikuchi M., Oka Y., Asano T.,

Biochem Biophys Res Commun 288:476-482(2001)

A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling.

Waterman H., Katz M., Rubin C., Shtiegman K., Lavi S., Elson A., Jovin T., Yarden Y.,

EMBO J 21:303-313(2002)

HIP1 and HIP12 display differential binding to F-actin, AP2, and clathrin. Identification of a novel interaction with clathrin light chain.

Legendre-Guillemin V., Metzler M., Charbonneau M., Gan L., Chopra V., Philie J., Hayden M.R., McPherson P.S.,

J. Biol. Chem. 277:19897-19904(2002)

Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors.

Soubeyran P., Kowanetz K., Szymkiewicz I., Langdon W.Y., Dikic I.,

Nature 416:183-187(2002)

A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins.

Polo S., Sigismund S., Faretta M., Guidi M., Capua M.R., Bossi G., Chen H., De Camilli P., Di Fiore P.P.,

Nature 416:451-455(2002)

Epsins and Vps27p/Hrs contain ubiquitin-binding domains that function in receptor endocytosis.

Shih S.C., Katzmann D.J., Schnell J.D., Sutanto M., Emr S.D., Hicke L.,

Nat. Cell Biol. 4:389-393(2002)

AP-1 as a regulator of cell life and death.

Shaulian E., Karin M.,

Nat Cell Biol 4:E131-6(2002)

Accessory protein recruitment motifs in clathrin-mediated endocytosis.

Brett T.J., Traub L.M., Fremont D.H.,

Structure 10:797-809(2002)

A ubiquitin-interacting motif (UIM) is essential for Eps15 and Eps15R ubiquitination.

Klapisz E., Sorokina I., Lemeer S., Pijnenburg M., Verkleij A.J., van Bergen en Henegouwen P.M.,

J Biol Chem 277:30746-30753(2002)

Cbl-directed monoubiquitination of CIN85 is involved in regulation of ligand-induced degradation of EGF receptors.

Haglund K., Shimokawa N., Szymkiewicz I., Dikic I.,

Proc. Natl. Acad. Sci. U.S.A. 99:12191-12196(2002)

hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl.

Hall A.B., Jura N., DaSilva J., Jang Y.J., Gong D., Bar-Sagi D.,

Curr Biol 13:308-314(2003)

Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.

Vijapurkar U., Kim M.S., Koland J.G.,

Exp Cell Res 284:291-302(2003)

Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene.

Lindvall C., Hou M., Komurasaki T., Zheng C., Henriksson M., Sedivy J.M., Bjorkholm M., Teh B.T., Nordenskjold M., Xu D.,

Cancer Res 63:1743-1747(2003)

Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation.

Haglund K., Sigismund S., Polo S., Szymkiewicz I., Di Fiore P.P., Dikic I.,

Nat Cell Biol 5:461-466(2003)

Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment.

Cheng Q.C., Tikhomirov O., Zhou W., Carpenter G.,

J Biol Chem 278:38421-38427(2003)

Sorting nexin 9 participates in clathrin-mediated endocytosis through interactions with the core components.

Lundmark R., Carlsson S.R.,

J. Biol. Chem. 278:46772-46781(2003)

Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling.

Agazie Y.M., Hayman M.J.,

Mol Cell Biol 23:7875-7886(2003)

Synaptojanin is recruited by endophilin to promote synaptic vesicle uncoating.

Verstreken P., Koh T.W., Schulze K.L., Zhai R.G., Hiesinger P.R., Zhou Y., Mehta S.Q., Cao Y., Roos J., Bellen H.J.,

Neuron 40:733-748(2003)

Endophilin is required for synaptic vesicle endocytosis by localizing synaptojanin.

Schuske K.R., Richmond J.E., Matthies D.S., Davis W.S., Runz S., Rube D.A., van der Bliek A.M., Jorgensen E.M.,

Neuron 40:749-762(2003)

Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor.

Ren Y., Meng S., Mei L., Zhao Z.J., Jove R., Wu J.,

J Biol Chem 279:8497-8505(2004)

Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells.

Kapoor G.S., Zhan Y., Johnson G.R., O'Rourke D.M.,

Mol Cell Biol 24:823-836(2004)

Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.

Zhang S.Q., Yang W., Kontaridis M.I., Bivona T.G., Wen G., Araki T., Luo J., Thompson J.A., Schraven B.L., Philips M.R., Neel B.G.,

Mol. Cell 13:341-355(2004)

Analysis of clathrin-mediated endocytosis of epidermal growth factor receptor by RNA interference.

Huang F., Khvorova A., Marshall W., Sorkin A.,

J. Biol. Chem. 279:16657-16661(2004)

Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases.

Marmor M.D., Yarden Y.,

Oncogene 23:2057-2070(2004)

The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells.

Maggiolini M., Vivacqua A., Fasanella G., Recchia A.G., Sisci D., Pezzi V., Montanaro D., Musti A.M., Picard D., Ando S.,

J Biol Chem 279:27008-27016(2004)

Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations.

Kassenbrock C.K., Anderson S.M.,

J Biol Chem 279:28017-28027(2004)

Memo mediates ErbB2-driven cell motility.

Marone R., Hess D., Dankort D., Muller W.J., Hynes N.E., Badache A.,

Nat. Cell Biol. 6:515-522(2004)

Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites.

Fan Y.X., Wong L., Deb T.B., Johnson G.R.,

J Biol Chem 279:38143-38150(2004)

A novel dynamin-associating molecule, formin-binding protein 17, induces tubular membrane invaginations and participates in endocytosis.

Kamioka Y., Fukuhara S., Sawa H., Nagashima K., Masuda M., Matsuda M., Mochizuki N.,

J. Biol. Chem. 279:40091-40099(2004)

Dap160/intersectin scaffolds the periactive zone to achieve high-fidelity endocytosis and normal synaptic growth.

Marie B., Sweeney S.T., Poskanzer K.E., Roos J., Kelly R.B., Davis G.W.,

Neuron 43:207-219(2004)

Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma.

Yamamoto T., Akisue T., Marui T., Nakatani T., Kawamoto T., Hitora T., Nagira K., Fujita I., Matsumoto K., Kurosaka M.,

Anticancer Res 24:2007-2010(2004)

The stimulatory action of amphiphysin on dynamin function is dependent on lipid bilayer curvature.

Yoshida Y., Kinuta M., Abe T., Liang S., Araki K., Cremona O., Di Paolo G., Moriyama Y., Yasuda T., De Camilli P., Takei K.,

EMBO J 23:3483-3491(2004)

Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment.

de Melker A.A., van der Horst G., Borst J.,

J Biol Chem 279:55465-55473(2004)

EGF-like factor epiregulin and amphiregulin expression is regulated by gonadotropins/cAMP in human ovarian follicular cells.

Freimann S., Ben-Ami I., Dantes A., Ron-El R., Amsterdam A.,

Biochem Biophys Res Commun 324:829-834(2004)

Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation.

Grovdal L.M., Stang E., Sorkin A., Madshus I.H.,

Exp Cell Res 300:388-395(2004)

Molecular model for a complete clathrin lattice from electron cryomicroscopy.

Fotin A., Cheng Y., Sliz P., Grigorieff N., Harrison S.C., Kirchhausen T., Walz T.,

Nature 432:573-579(2004)

Structure of an auxilin-bound clathrin coat and its implications for the mechanism of uncoating.

Fotin A., Cheng Y., Grigorieff N., Walz T., Harrison S.C., Kirchhausen T.,

Nature 432:649-653(2004)

AP-1 subunits: quarrel and harmony among siblings.

Hess J., Angel P., Schorpp-Kistner M.,

J Cell Sci 117:5965-5973(2004)

Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation.

Citri A., Gan J., Mosesson Y., Vereb G., Szollosi J., Yarden Y.,

EMBO Rep 5:1165-1170(2004)

A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation.

Montagner A., Yart A., Dance M., Perret B., Salles J.P., Raynal P.,

J Biol Chem 280:5350-5360(2005)

Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.

Xu W., Yuan X., Xiang Z., Mimnaugh E., Marcu M., Neckers L.,

Nat Struct Mol Biol 12:120-126(2005)

BAR domains and membrane curvature: bringing your curves to the BAR.

Gallop J.L., McMahon H.T.,

Biochem Soc Symp 2005:223-231(2005)

Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.

Thelemann A., Petti F., Griffin G., Iwata K., Hunt T., Settinari T., Fenyo D., Gibson N., Haley J.D.,

Mol Cell Proteomics 4:356-376(2005)

Clathrin-independent endocytosis of ubiquitinated cargos.

Sigismund S., Woelk T., Puri C., Maspero E., Tacchetti C., Transidico P., Di Fiore P.P., Polo S.,

Proc Natl Acad Sci U S A 102:2760-2765(2005)

SNX9 regulates dynamin assembly and is required for efficient clathrin-mediated endocytosis.

Soulet F., Yarar D., Leonard M., Schmid S.L.,

Mol. Biol. Cell 16:2058-2067(2005)

PI 3-kinase p110beta: a new target for antithrombotic therapy.

Jackson S.P., Schoenwaelder S.M., Goncalves I., Nesbitt W.S., Yap C.L., Wright C.E., Kenche V., Anderson K.E., Dopheide S.M., Yuan Y., Sturgeon S.A., Prabaharan H., Thompson P.E., Smith G.D., Shepherd P.R., Daniele N., Kulkarni S., Abbott B., Salem H.H.,

Nat Med 11:507-514(2005)

Caenorhabditis elegans RME-6 is a novel regulator of RAB-5 at the clathrin-coated pit.

Sato M., Sato K., Fonarev P., Huang C.-J., Liou W., Grant B.D.,

Nat. Cell Biol. 7:559-569(2005)

Sprouty2 acts at the Cbl/CIN85 interface to inhibit epidermal growth factor receptor downregulation.

Haglund K., Schmidt M.H., Wong E.S., Guy G.R., Dikic I.,

EMBO Rep. 6:635-641(2005)

An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway.

Shin H.W., Hayashi M., Christoforidis S., Lacas-Gervais S., Hoepfner S., Wenk M.R., Modregger J., Uttenweiler-Joseph S., Wilm M., Nystuen A., Frankel W.N., Solimena M., De Camilli P., Zerial M.,

J Cell Biol 170:607-618(2005)

The Fos family of transcription factors and their role in tumourigenesis.

Milde-Langosch K.,

Eur J Cancer 41:2449-2461(2005)

Individual phosphoinositide 3-kinase C2alpha domain activities independently regulate clathrin function.

Gaidarov I., Zhao Y., Keen J.H.,

J. Biol. Chem. 280:40766-40772(2005)

The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.

Vivacqua A., Bonofiglio D., Recchia A.G., Musti A.M., Picard D., Ando S., Maggiolini M.,

Mol Endocrinol 20:631-646(2006)

Dynamin and the actin cytoskeleton cooperatively regulate plasma membrane invagination by BAR and F-BAR proteins.

Itoh T., Erdmann K.S., Roux A., Habermann B., Werner H., De Camilli P.,

Dev. Cell 9:791-804(2005)

Cbl escapes Cdc42-mediated inhibition by downregulation of the adaptor molecule betaPix.

Schmidt M.H.H., Husnjak K., Szymkiewicz I., Haglund K., Dikic I.,

Oncogene 25:3071-3078(2006)

Rab5-activating protein 6, a novel endosomal protein with a role in endocytosis.

Hunker C.M., Galvis A., Kruk I., Giambini H., Veisaga M.L., Barbieri M.A.,

Biochem. Biophys. Res. Commun. 340:967-975(2006)

Molecular switches involving the AP-2 beta2 appendage regulate endocytic cargo selection and clathrin coat assembly.

Edeling M.A., Mishra S.K., Keyel P.A., Steinhauser A.L., Collins B.M., Roth R., Heuser J.E., Owen D.J., Traub L.M.,

Dev. Cell 10:329-342(2006)

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., Balla T., Weiss W.A., Williams R.L., Shokat K.M.,

Cell 125:733-747(2006)

A burst of auxilin recruitment determines the onset of clathrin-coated vesicle uncoating.

Massol R.H., Boll W., Griffin A.M., Kirchhausen T.,

Proc Natl Acad Sci U S A 103:10265-10270(2006)

17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30.

Vivacqua A., Bonofiglio D., Albanito L., Madeo A., Rago V., Carpino A., Musti A.M., Picard D., Ando S., Maggiolini M.,

Mol Pharmacol 70:1414-1423(2006)

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

Wang S.E., Narasanna A., Perez-Torres M., Xiang B., Wu F.Y., Yang S., Carpenter G., Gazdar A.F., Muthuswamy S.K., Arteaga C.L.,

Cancer Cell 10:25-38(2006)

Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates.

Walton G.M., Chen W.S., Rosenfeld M.G., Gill G.N.,

J Biol Chem 265:1750-1754(1990)

PGE2 up-regulates EGF-like growth factor biosynthesis in human granulosa cells: new insights into the coordination between PGE2 and LH in ovulation.

Ben-Ami I., Freimann S., Armon L., Dantes A., Strassburger D., Friedler S., Raziel A., Seger R., Ron-El R., Amsterdam A.,

Mol Hum Reprod 12:593-599(2006)

Identification of two epidermal growth factor-sensitive tyrosine phosphorylation sites of phospholipase C-gamma in intact HSC-1 cells.

Whal M.I., Nishibe S., Kim J.W., Kim H.K., Rhee S.G., Carpenter G.,

J. Biol. Chem. 265:3944-3948(1990)

Role of the AP2 beta-appendage hub in recruiting partners for clathrin-coated vesicle assembly.

Schmid E.M., Ford M.G.J., Burtey A., Praefcke G.J.K., Peak-Chew S.-Y., Mills I.G., Benmerah A., McMahon H.T.,

PLoS Biol. 4:E262-E262(2006)

Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.

Li Z., Mei Y., Liu X., Zhou M.,

Cell. Signal. 19:466-471(2007)

Cargo regulates clathrin-coated pit dynamics.

Puthenveedu M.A., von Zastrow M.,

Cell 127:113-124(2006)

Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.

Xu W., Yuan X., Beebe K., Xiang Z., Neckers L.,

Mol Cell Biol 27:220-228(2007)

Identification of autophosphorylation sites of HER2/neu.

Hazan R., Margolis B., Dombalagian M., Ullrich A., Zilberstein A., Schlessinger J.,

Cell Growth Differ 1:3-7(1990)

Two synaptojanin 1 isoforms are recruited to clathrin-coated pits at different stages.

Perera R.M., Zoncu R., Lucast L., De Camilli P., Toomre D.,

Proc Natl Acad Sci U S A 103:19332-19337(2006)

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.

Minami Y., Shimamura T., Shah K., LaFramboise T., Glatt K.A., Liniker E., Borgman C.L., Haringsma H.J., Feng W., Weir B.A., Lowell A.M., Lee J.C., Wolf J., Shapiro G.I., Wong K.K., Meyerson M., Thomas R.K.,

Oncogene 26:5023-5027(2007)

Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.

Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., Gomis R.R., Manova-Todorova K., Massague J.,

Nature 446:765-770(2007)

Curved EFC/F-BAR-domain dimers are joined end to end into a filament for membrane invagination in endocytosis.

Shimada A., Niwa H., Tsujita K., Suetsugu S., Nitta K., Hanawa-Suetsugu K., Akasaka R., Nishino Y., Toyama M., Chen L., Liu Z.-J., Wang B.C., Yamamoto M., Terada T., Miyazawa A., Tanaka A., Sugano S., Shirouzu M., Yokoyama S.,

Cell 129:761-772(2007)

Structure and analysis of FCHo2 F-BAR domain: a dimerizing and membrane recruitment module that effects membrane curvature.

Henne W.M., Kent H.M., Ford M.G., Hegde B.G., Daumke O., Butler P.J., Mittal R., Langen R., Evans P.R., McMahon H.T.,

Structure 15:839-852(2007)

Identification and characterization of novel spliced variants of neuregulin 4 in prostate cancer.

Hayes N.V., Blackburn E., Smart L.V., Boyle M.M., Russell G.A., Frost T.M., Morgan B.J., Baines A.J., Gullick W.J.,

Clin Cancer Res 13:3147-3155(2007)

SNX9 couples actin assembly to phosphoinositide signals and is required for membrane remodeling during endocytosis.

Yarar D., Waterman-Storer C.M., Schmid S.L.,

Dev. Cell 13:43-56(2007)

Sorting nexin 9 interacts with dynamin 1 and N-WASP and coordinates synaptic vesicle endocytosis.

Shin N., Lee S., Ahn N., Kim S.A., Ahn S.G., YongPark Z., Chang S.,

J Biol Chem 282:28939-28950(2007)

A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway.

Erdmann K.S., Mao Y., McCrea H.J., Zoncu R., Lee S., Paradise S., Modregger J., Biemesderfer D., Toomre D., De Camilli P.,

Dev. Cell 13:377-390(2007)

ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.

Revillion F., Lhotellier V., Hornez L., Bonneterre J., Peyrat J.P.,

Ann Oncol 19:73-80(2008)

A motif in the clathrin heavy chain required for the Hsc70/auxilin uncoating reaction.

Rapoport I., Boll W., Yu A., Bocking T., Kirchhausen T.,

Mol Biol Cell 19:405-413(2008)

Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.

Fan Y.X., Wong L., Ding J., Spiridonov N.A., Johnson R.C., Johnson G.R.,

J Biol Chem 283:1588-1596(2008)

Memo is homologous to nonheme iron dioxygenases and binds an ErbB2-derived phosphopeptide in its vestigial active site.

Qiu C., Lienhard S., Hynes N.E., Badache A., Leahy D.J.,

J. Biol. Chem. 283:2734-2740(2008)

Human corneal epithelial cell proliferation by epiregulin and its cross-induction by other EGF family members.

Morita S., Shirakata Y., Shiraishi A., Kadota Y., Hashimoto K., Higashiyama S., Ohashi Y.,

Mol Vis 13:2119-2128(2007)

The dual phosphatase activity of synaptojanin1 is required for both efficient synaptic vesicle endocytosis and reavailability at nerve terminals.

Mani M., Lee S.Y., Lucast L., Cremona O., Di Paolo G., De Camilli P., Ryan T.A.,

Neuron 56:1004-1018(2007)

Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas.

Li S., Takeuchi F., Wang J.A., Fan Q., Komurasaki T., Billings E.M., Pacheco-Rodriguez G., Moss J., Darling T.N.,

Proc Natl Acad Sci U S A 105:3539-3544(2008)

SNX9 regulates tubular invagination of the plasma membrane through interaction with actin cytoskeleton and dynamin 2.

Shin N., Ahn N., Chang-Ileto B., Park J., Takei K., Ahn S.G., Kim S.A., Di Paolo G., Chang S.,

J. Cell Sci. 121:1252-1263(2008)

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.

Trowe T., Boukouvala S., Calkins K., Cutler R.E. Jr., Fong R., Funke R., Gendreau S.B., Kim Y.D., Miller N., Woolfrey J.R., Vysotskaia V., Yang J.P., Gerritsen M.E., Matthews D.J., Lamb P., Heuer T.S.,

Clin Cancer Res 14:2465-2475(2008)

Expression of epiregulin, a novel epidermal growth factor ligand associated with prognosis in human oral squamous cell carcinomas.

Shigeishi H., Higashikawa K., Hiraoka M., Fujimoto S., Mitani Y., Ohta K., Takechi M., Kamata N.,

Oncol Rep 19:1557-1564(2008)

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., Garcia-Echeverria C.,

Mol Cancer Ther 7:1851-1863(2008)

Brk is coamplified with ErbB2 to promote proliferation in breast cancer.

Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., Miller W.T., Muthuswamy S.K.,

Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008)

System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties.

Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J., MacBeath G.,

Chem. Biol. 15:808-817(2008)

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Folkes A.J., Ahmadi K., Alderton W.K., Alix S., Baker S.J., Box G., Chuckowree I.S., Clarke P.A., Depledge P., Eccles S.A., Friedman L.S., Hayes A., Hancox T.C., Kugendradas A., Lensun L., Moore P., Olivero A.G., Pang J., Shuttleworth S.J.,

J Med Chem 51:5522-5532(2008)

Actin binding by Hip1 (huntingtin-interacting protein 1) and Hip1R (Hip1-related protein) is regulated by clathrin light chain.

Wilbur J.D., Chen C.-Y., Manalo V., Hwang P.K., Fletterick R.J., Brodsky F.M.,

J. Biol. Chem. 283:32870-32879(2008)

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., Baselga J.,

Cancer Res 68:8022-8030(2008)

EGF-like growth factors as LH mediators in the human corpus luteum.

Ben-Ami I., Armon L., Freimann S., Strassburger D., Ron-El R., Amsterdam A.,

Hum Reprod 24:176-184(2009)

Epiregulin expression by Ets-1 and ERK signaling pathway in Ki-ras-transformed cells.

Cho M.C., Choi H.S., Lee S., Kim B.Y., Jung M., Park S.N., Yoon D.Y.,

Biochem Biophys Res Commun 377:832-837(2008)

Memo-RhoA-mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells.

Zaoui K., Honore S., Isnardon D., Braguer D., Badache A.,

J Cell Biol 183:401-408(2008)

Coordinated regulation of AP2 uncoating from clathrin-coated vesicles by rab5 and hRME-6.

Semerdjieva S., Shortt B., Maxwell E., Singh S., Fonarev P., Hansen J., Schiavo G., Grant B.D., Smythe E.,

J Cell Biol 183:499-511(2008)

Epsin 1 is involved in recruitment of ubiquitinated EGF receptors into clathrin-coated pits.

Kazazic M., Bertelsen V., Pedersen K.W., Vuong T.T., Grandal M.V., Rodland M.S., Traub L.M., Stang E., Madshus I.H.,

Traffic 10:235-245(2009)

SNX9 - a prelude to vesicle release.

Lundmark R., Carlsson S.R.,

J Cell Sci 122:5-11(2009)

Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells.

Zhang J., Iwanaga K., Choi K.C., Wislez M., Raso M.G., Wei W., Wistuba I.I., Kurie J.M.,

Cancer Prev Res (Phila) 1:201-207(2008)

Cargo and dynamin regulate clathrin-coated pit maturation.

Loerke D., Mettlen M., Yarar D., Jaqaman K., Jaqaman H., Danuser G., Schmid S.L.,

PLoS Biol 7:e57-e57(2009)

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., Sliwkowski M.X.,

Cancer Cell 15:429-440(2009)

Endocytic accessory proteins are functionally distinguished by their differential effects on the maturation of clathrin-coated pits.

Mettlen M., Stoeber M., Loerke D., Antonescu C.N., Danuser G., Schmid S.L.,

Mol. Biol. Cell 20:3251-3260(2009)

A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism.

Mao Y., Balkin D.M., Zoncu R., Erdmann K.S., Tomasini L., Hu F., Jin M.M., Hodsdon M.E., De Camilli P.,

EMBO J. 28:1831-1842(2009)

Molecular circuitry of endocytosis at nerve terminals.

Dittman J., Ryan T.A.,

Annu Rev Cell Dev Biol 25:133-160(2009)

Rab GTPases as coordinators of vesicle traffic.

Stenmark H.,

Nat. Rev. Mol. Cell Biol. 10:513-525(2009)

Targeting the phosphoinositide 3-kinase pathway in cancer.

Liu P., Cheng H., Roberts T.M., Zhao J.J.,

Nat Rev Drug Discov 8:627-644(2009)

Tickets to ride: selecting cargo for clathrin-regulated internalization.

Traub L.M.,

Nat Rev Mol Cell Biol 10:583-596(2009)

Endocytosis and signalling: intertwining molecular networks.

Sorkin A., von Zastrow M.,

Nat Rev Mol Cell Biol 10:609-622(2009)

Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function.

Wada T., Qian X.L., Greene M.I.,

Cell 61:1339-1347(1990)

A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.

Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I., Huang C.H., Kinzler K.W., Vogelstein B., Amzel L.M.,

Proc. Natl. Acad. Sci. U.S.A. 106:16996-17001(2009)

Eps15: a multifunctional adaptor protein regulating intracellular trafficking.

van Bergen En Henegouwen P.M.,

Cell Commun Signal 7:24-24(2009)

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., Cortot A.B., Chirieac L., Iacob R.E., Padera R., Engen J.R., Wong K.K., Eck M.J., Gray N.S., Janne P.A.,

Nature 462:1070-1074(2009)

Structure of clathrin coat with bound Hsc70 and auxilin: mechanism of Hsc70-facilitated disassembly.

Xing Y., Bocking T., Wolf M., Grigorieff N., Kirchhausen T., Harrison S.C.,

EMBO J 29:655-665(2010)

Coordinated actions of actin and BAR proteins upstream of dynamin at endocytic clathrin-coated pits.

Ferguson S.M., Ferguson S., Raimondi A., Paradise S., Shen H., Mesaki K., Ferguson A., Destaing O., Ko G., Takasaki J., Cremona O., O' Toole E., De Camilli P.,

Dev Cell 17:811-822(2009)

Internalization and down-regulation of the human epidermal growth factor receptor are regulated by the carboxyl-terminal tyrosines.

Helin K., Beguinot L.,

J Biol Chem 266:8363-8368(1991)

Cargo- and adaptor-specific mechanisms regulate clathrin-mediated endocytosis.

Mettlen M., Loerke D., Yarar D., Danuser G., Schmid S.L.,

J Cell Biol 188:919-933(2010)

G domain dimerization controls dynamin's assembly-stimulated GTPase activity.

Chappie J.S., Acharya S., Leonard M., Schmid S.L., Dyda F.,

Nature 465:435-440(2010)

FCHo proteins are nucleators of clathrin-mediated endocytosis.

Henne W.M., Boucrot E., Meinecke M., Evergren E., Vallis Y., Mittal R., McMahon H.T.,

Science 328:1281-1284(2010)

Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Herman S.E., Gordon A.L., Wagner A.J., Heerema N.A., Zhao W., Flynn J.M., Jones J., Andritsos L., Puri K.D., Lannutti B.J., Giese N.A., Zhang X., Wei L., Byrd J.C., Johnson A.J.,

Blood 116:2078-2088(2010)

The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway.

Liu M., Yang Y., Wang C., Sun L., Mei C., Yao W., Liu Y., Shi Y., Qiu S., Fan J., Cai X., Zha X.,

Arch Biochem Biophys 502:89-95(2010)

Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.

Sun M., Hillmann P., Hofmann B.T., Hart J.R., Vogt P.K.,

Proc Natl Acad Sci U S A 107:15547-15552(2010)

Structure of the PTEN-like region of auxilin, a detector of clathrin-coated vesicle budding.

Guan R., Dai H., Han D., Harrison S.C., Kirchhausen T.,

Structure 18:1191-1198(2010)

ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells.

Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.,

Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010)

Intersectin 1 forms complexes with SGIP1 and Reps1 in clathrin-coated pits.

Dergai O., Novokhatska O., Dergai M., Skrypkina I., Tsyba L., Moreau J., Rynditch A.,

Biochem. Biophys. Res. Commun. 402:408-413(2010)

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Vigil D., Cherfils J., Rossman K.L., Der C.J.,

Nat Rev Cancer 10:842-857(2010)

Localization of low molecular weight GTP binding proteins to exocytic and endocytic compartments.

Chavrier P., Parton R.G., Hauri H.P., Simons K., Zerial M.,

Cell 62:317-329(1990)

Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.

Oliveras-Ferraros C., Massaguer Vall-Llovera A., Carrion Salip D., Vazquez-Martin A., Cufi S., Queralt B., Martin-Castillo B., Brunet J., de Llorens R., Menendez J.A.,

Invest New Drugs 30:846-852(2012)

Local clustering of transferrin receptors promotes clathrin-coated pit initiation.

Liu A.P., Aguet F., Danuser G., Schmid S.L.,

J Cell Biol 191:1381-1393(2010)

Single-molecule analysis of a molecular disassemblase reveals the mechanism of Hsc70-driven clathrin uncoating.

Bocking T., Aguet F., Harrison S.C., Kirchhausen T.,

Nat Struct Mol Biol 18:295-301(2011)

Synaptojanin 1-mediated PI(4,5)P2 hydrolysis is modulated by membrane curvature and facilitates membrane fission.

Chang-Ileto B., Frere S.G., Chan R.B., Voronov S.V., Roux A., Di Paolo G.,

Dev Cell 20:206-218(2011)

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

Prasad G., Sottero T., Yang X., Mueller S., James C.D., Weiss W.A., Polley M.Y., Ozawa T., Berger M.S., Aftab D.T., Prados M.D., Haas-Kogan D.A.,

Neuro Oncol 13:384-392(2011)

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.

Chakrabarty A., Sanchez V., Kuba M.G., Rinehart C., Arteaga C.L.,

Proc Natl Acad Sci U S A 109:2718-2723(2012)

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.

Cargnello M., Roux P.P.,

Microbiol Mol Biol Rev 75:50-83(2011)

Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.

Sun T., Aceto N., Meerbrey K.L., Kessler J.D., Zhou C., Migliaccio I., Nguyen D.X., Pavlova N.N., Botero M., Huang J., Bernardi R.J., Schmitt E., Hu G., Li M.Z., Dephoure N., Gygi S.P., Rao M., Creighton C.J., Westbrook T.F.,

Cell 144:703-718(2011)

A high precision survey of the molecular dynamics of mammalian clathrin-mediated endocytosis.

Taylor M.J., Perrais D., Merrifield C.J.,

PLoS Biol 9:e1000604-e1000604(2011)

A sequential mechanism for clathrin cage disassembly by 70-kDa heat-shock cognate protein (Hsc70) and auxilin.

Rothnie A., Clarke A.R., Kuzmic P., Cameron A., Smith C.J.,

Proc Natl Acad Sci U S A 108:6927-6932(2011)

Tyrosine kinase activity is essential for the association of phospholipase C-gamma with the epidermal growth factor receptor.

Margolis B., Bellot F., Honegger A.M., Ullrich A., Schlessinger J., Zilberstein A.,

Mol Cell Biol 10:435-441(1990)

Phosphatidylinositol-(4,5)-bisphosphate regulates clathrin-coated pit initiation, stabilization, and size.

Antonescu C.N., Aguet F., Danuser G., Schmid S.L.,

Mol Biol Cell 22:2588-2600(2011)

A drug targeting only p110alpha can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.

Jamieson S., Flanagan J.U., Kolekar S., Buchanan C., Kendall J.D., Lee W.J., Rewcastle G.W., Denny W.A., Singh R., Dickson J., Baguley B.C., Shepherd P.R.,

Biochem J 438:53-62(2011)

Epiregulin as a marker for the initial steps of ovarian cancer development.

Amsterdam A., Shezen E., Raanan C., Slilat Y., Ben-Arie A., Prus D., Schreiber L.,

Int J Oncol 39:1165-1172(2011)

Molecular mechanism and physiological functions of clathrin-mediated endocytosis.

McMahon H.T., Boucrot E.,

Nat Rev Mol Cell Biol 12:517-533(2011)

Dynamics of the phosphoinositide 3-kinase p110delta interaction with p85alpha and membranes reveals aspects of regulation distinct from p110alpha.

Burke J.E., Vadas O., Berndt A., Finegan T., Perisic O., Williams R.L.,

Structure 19:1127-1137(2011)

MEMO associated with an ErbB2 receptor phosphopeptide reveals a new phosphotyrosine motif.

Feracci M., Pimentel C., Bornet O., Roche P., Salaun D., Badache A., Guerlesquin F.,

FEBS Lett 585:2688-2692(2011)

Actin dynamics counteract membrane tension during clathrin-mediated endocytosis.

Boulant S., Kural C., Zeeh J.C., Ubelmann F., Kirchhausen T.,

Nat Cell Biol 13:1124-1131(2011)

Crystal structure of nucleotide-free dynamin.

Faelber K., Posor Y., Gao S., Held M., Roske Y., Schulze D., Haucke V., Noe F., Daumke O.,

Nature 477:556-560(2011)

The crystal structure of dynamin.

Ford M.G., Jenni S., Nunnari J.,

Nature 477:561-566(2011)

A pseudoatomic model of the dynamin polymer identifies a hydrolysis-dependent powerstroke.

Chappie J.S., Mears J.A., Fang S., Leonard M., Schmid S.L., Milligan R.A., Hinshaw J.E., Dyda F.,

Cell 147:209-222(2011)

Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.

Chang K.Y., Tsai S.Y., Wu C.M., Yen C.J., Chuang B.F., Chang J.Y.,

Clin Cancer Res 17:7116-7126(2011)

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

Kancha R.K., von Bubnoff N., Bartosch N., Peschel C., Engh R.A., Duyster J.,

PLoS One 6:e26760-e26760(2011)

Recruitment of endophilin to clathrin-coated pit necks is required for efficient vesicle uncoating after fission.

Milosevic I., Giovedi S., Lou X., Raimondi A., Collesi C., Shen H., Paradise S., O'Toole E., Ferguson S., Cremona O., De Camilli P.,

Neuron 72:587-601(2011)

Epiregulin (EREG) variation is associated with susceptibility to tuberculosis.

Thuong N.T., Hawn T.R., Chau T.T., Bang N.D., Yen N.T., Thwaites G.E., Teo Y.Y., Seielstad M., Hibberd M., Lan N.T., Caws M., Farrar J.J., Dunstan S.J.,

Genes Immun 13:275-281(2012)

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Maira S.M., Pecchi S., Huang A., Burger M., Knapp M., Sterker D., Schnell C., Guthy D., Nagel T., Wiesmann M., Brachmann S., Fritsch C., Dorsch M., Chene P., Shoemaker K., De Pover A., Menezes D., Martiny-Baron G., Voliva C.F.,

Mol Cancer Ther 11:317-328(2012)

Dynamin, a membrane-remodelling GTPase.

Ferguson S.M., De Camilli P.,

Nat Rev Mol Cell Biol 13:75-88(2012)

The role of ubiquitylation in receptor endocytosis and endosomal sorting.

Haglund K., Dikic I.,

J Cell Sci 125:265-275(2012)

A feedback loop between dynamin and actin recruitment during clathrin-mediated endocytosis.

Taylor M.J., Lampe M., Merrifield C.J.,

PLoS Biol 10:e1001302-e1001302(2012)

Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers.

Yun J., Song S.H., Park J., Kim H.P., Yoon Y.K., Lee K.H., Han S.W., Oh D.Y., Im S.A., Bang Y.J., Kim T.Y.,

Lab Invest 92:1033-1044(2012)

Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent.

Ni J., Liu Q., Xie S., Carlson C., Von T., Vogel K., Riddle S., Benes C., Eck M., Roberts T., Gray N., Zhao J.,

Cancer Discov 2:425-433(2012)

The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.

Utermark T., Rao T., Cheng H., Wang Q., Lee S.H., Wang Z.C., Iglehart J.D., Roberts T.M., Muller W.J., Zhao J.J.,

Genes Dev 26:1573-1586(2012)

The epsin protein family: coordinators of endocytosis and signaling.

Sen A., Madhivanan K., Mukherjee D., Aguilar R.C.,

Biomol Concepts 3:117-126(2012)

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Sunaga N., Kaira K., Imai H., Shimizu K., Nakano T., Shames D.S., Girard L., Soh J., Sato M., Iwasaki Y., Ishizuka T., Gazdar A.F., Minna J.D., Mori M.,

Oncogene 32:4034-4042(2013)

Demethylation of epiregulin gene by histone demethylase FBXL11 and BCL6 corepressor inhibits osteo/dentinogenic differentiation.

Du J., Ma Y., Ma P., Wang S., Fan Z.,

Stem Cells 31:126-136(2013)

Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Bose R., Kavuri S.M., Searleman A.C., Shen W., Shen D., Koboldt D.C., Monsey J., Goel N., Aronson A.B., Li S., Ma C.X., Ding L., Mardis E.R., Ellis M.J.,

Cancer Discov 3:224-237(2013)

Cooperative recruitment of dynamin and BIN/amphiphysin/Rvs (BAR) domain-containing proteins leads to GTP-dependent membrane scission.

Meinecke M., Boucrot E., Camdere G., Hon W.C., Mittal R., McMahon H.T.,

J Biol Chem 288:6651-6661(2013)

Regulation of small GTPases by GEFs, GAPs, and GDIs.

Cherfils J., Zeghouf M.,

Physiol Rev 93:269-309(2013)

Divergent modes for cargo-mediated control of clathrin-coated pit dynamics.

Soohoo A.L., Puthenveedu M.A.,

Mol Biol Cell 24:1725-1734(2013)

Gene expression profiling and association studies implicate the neuregulin signaling pathway in Behcet's disease susceptibility.

Xavier J.M., Krug T., Davatchi F., Shahram F., Fonseca B.V., Jesus G., Barcelos F., Vedes J., Salgado M., Abdollahi B.S., Nadji A., Moraes-Fontes M.F., Shafiee N.M., Ghaderibarmi F., Vaz Patto J., Crespo J., Oliveira S.A.,

J Mol Med (Berl) 91:1013-1023(2013)

Transformation of polarized epithelial cells by apical mistrafficking of epiregulin.

Singh B., Bogatcheva G., Washington M.K., Coffey R.J.,

Proc Natl Acad Sci U S A 110:8960-8965(2013)

Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate.

Posor Y., Eichhorn-Gruenig M., Puchkov D., Schoneberg J., Ullrich A., Lampe A., Muller R., Zarbakhsh S., Gulluni F., Hirsch E., Krauss M., Schultz C., Schmoranzer J., Noe F., Haucke V.,

Nature 499:233-237(2013)

Cholesteatoma fibroblasts promote epithelial cell proliferation through overexpression of epiregulin.

Yoshikawa M., Kojima H., Yaguchi Y., Okada N., Saito H., Moriyama H.,

PLoS One 8:e66725-e66725(2013)

Epiregulin can promote proliferation of stem cells from the dental apical papilla via MEK/Erk and JNK signalling pathways.

Cao Y., Xia D.S., Qi S.R., Du J., Ma P., Wang S.L., Fan Z.P.,

Cell Prolif 46:447-456(2013)

Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.

Collier T.S., Diraviyam K., Monsey J., Shen W., Sept D., Bose R.,

J Biol Chem 288:25254-25264(2013)

Dual role of BAR domain-containing proteins in regulating vesicle release catalyzed by the GTPase, dynamin-2.

Neumann S., Schmid S.L.,

J Biol Chem 288:25119-25128(2013)

[Correlation between the presence of Kras mutation and the presence of the proteins epiregulin and amphiregulin in colon cancer tissue].

Levi Y., Barshack I., Avivi K., Bar-ILan D., Gutman M., Aderka D., Berger R., Yacobi R.,

Harefuah 152:326-329(2013)

Advances in analysis of low signal-to-noise images link dynamin and AP2 to the functions of an endocytic checkpoint.

Aguet F., Antonescu C.N., Mettlen M., Schmid S.L., Danuser G.,

Dev Cell 26:279-291(2013)

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

Rexer B.N., Ghosh R., Narasanna A., Estrada M.V., Chakrabarty A., Song Y., Engelman J.A., Arteaga C.L.,

Clin Cancer Res 19:5390-5401(2013)

Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor alpha (ERalpha).

Tsai C.L., Wu H.M., Lin C.Y., Lin Y.J., Chao A., Wang T.H., Hsueh S., Lai C.H., Wang H.S.,

PLoS One 8:e72999-e72999(2013)

Cargo recognition in clathrin-mediated endocytosis.

Traub L.M., Bonifacino J.S.,

Cold Spring Harb Perspect Biol 5:a016790-a016790(2013)

High epiregulin expression in human U87 glioma cells relies on IRE1alpha and promotes autocrine growth through EGF receptor.

Auf G., Jabouille A., Delugin M., Guerit S., Pineau R., North S., Platonova N., Maitre M., Favereaux A., Vajkoczy P., Seno M., Bikfalvi A., Minchenko D., Minchenko O., Moenner M.,

BMC Cancer 13:597-597(2013)

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.

Jonker D.J., Karapetis C.S., Harbison C., O'Callaghan C.J., Tu D., Simes R.J., Malone D.P., Langer C., Tebbutt N., Price T.J., Shapiro J., Siu L.L., Wong R.P., Bjarnason G., Moore M.J., Zalcberg J.R., Khambata-Ford S.,

Br J Cancer 110:648-655(2014)

Ubiquitin-dependent sorting in endocytosis.

Piper R.C., Dikic I., Lukacs G.L.,

Cold Spring Harb Perspect Biol 6:0-0(2014)

Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma.

Kohsaka S., Hinohara K., Wang L., Nishimura T., Urushido M., Yachi K., Tsuda M., Tanino M., Kimura T., Nishihara H., Gotoh N., Tanaka S.,

Neuro Oncol 16:960-970(2014)

BAR domain scaffolds in dynamin-mediated membrane fission.

Daumke O., Roux A., Haucke V.,

Cell 156:882-892(2014)

Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro.

Meisenhelder J., Suh P.G., Rhee S.G., Hunter T.,

Cell 57:1109-1122(1989)

Regulation of clathrin-mediated endocytosis by dynamic ubiquitination and deubiquitination.

Weinberg J.S., Drubin D.G.,

Curr Biol 24:951-959(2014)

Evidence that TSC2 acts as a transcription factor and binds to and represses the promoter of Epiregulin.

Pradhan S.A., Rather M.I., Tiwari A., Bhat V.K., Kumar A.,

Nucleic Acids Res 42:6243-6255(2014)

Molecular structure, function, and dynamics of clathrin-mediated membrane traffic.

Kirchhausen T., Owen D., Harrison S.C.,

Cold Spring Harb Perspect Biol 6:a016725-a016725(2014)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.

Takahashi N., Yamada Y., Furuta K., Honma Y., Iwasa S., Takashima A., Kato K., Hamaguchi T., Shimada Y.,

Br J Cancer 110:2716-2727(2014)

Epiregulin promotes the emergence and proliferation of adult liver progenitor cells.

Tomita K., Haga H., Mizuno K., Katsumi T., Sato C., Okumoto K., Nishise Y., Watanabe H., Saito T., Ueno Y.,

Am J Physiol Gastrointest Liver Physiol 307:G50-7(2014)

Epiregulin (EREG) and human V-ATPase (TCIRG1): genetic variation, ethnicity and pulmonary tuberculosis susceptibility in Guinea-Bissau and The Gambia.

White M.J., Tacconelli A., Chen J.S., Wejse C., Hill P.C., Gomes V.F., Velez-Edwards D.R., Ostergaard L.J., Hu T., Moore J.H., Novelli G., Scott W.K., Williams S.M., Sirugo G.,

Genes Immun 15:370-377(2014)

"RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway.

Cseh B., Doma E., Baccarini M.,

FEBS Lett 588:2398-2406(2014)

Inositol lipid phosphatases in membrane trafficking and human disease.

Billcliff P.G., Lowe M.,

Biochem J 461:159-175(2014)

Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.

de Martino M., Zhuang D., Klatte T., Rieken M., Roupret M., Xylinas E., Clozel T., Krzywinski M., Elemento O., Shariat S.F.,

Cancer Biol Ther 15:1239-1247(2014)

A role of OCRL in clathrin-coated pit dynamics and uncoating revealed by studies of Lowe syndrome cells.

Nandez R., Balkin D.M., Messa M., Liang L., Paradise S., Czapla H., Hein M.Y., Duncan J.S., Mann M., De Camilli P.,

Elife 3:e02975-e02975(2014)

Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent.

Wakatsuki T., Stintzing S., Zhang W., Yang D., Azuma M., Ning Y., Yamauchi S., Matsusaka S., Volz N.B., Sunakawa Y., Koizumi W., Watanabe M., Barzi A., El Khoueiry A.B., Shah M.A., Lenz H.J.,

Pharmacogenet Genomics 24:539-547(2014)

Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation.

Li M.Y., Lai P.L., Chou Y.T., Chi A.P., Mi Y.Z., Khoo K.H., Chang G.D., Wu C.W., Meng T.C., Chen G.C.,

Oncogene 34:3791-3803(2015)

Rab proteins and the compartmentalization of the endosomal system.

Wandinger-Ness A., Zerial M.,

Cold Spring Harb Perspect Biol 6:a022616-a022616(2014)

All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor.

Margolis B.L., Lax I., Kris R., Dombalagian M., Honegger A.M., Howk R., Givol D., Ullrich A., Schlessinger J.,

J. Biol. Chem. 264:10667-10671(1989)

Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity.

Hu Z., Wan X., Hao R., Zhang H., Li L., Li L., Xie Q., Wang P., Gao Y., Chen S., Wei M., Luan Z., Zhang A., Huang N., Chen L.,

PLoS One 10:e0123623-e0123623(2015)

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.

Ng C.K., Martelotto L.G., Gauthier A., Wen H.C., Piscuoglio S., Lim R.S., Cowell C.F., Wilkerson P.M., Wai P., Rodrigues D.N., Arnould L., Geyer F.C., Bromberg S.E., Lacroix-Triki M., Penault-Llorca F., Giard S., Sastre-Garau X., Natrajan R., Reis-Filho J.S.,

Genome Biol 16:107-107(2015)

The role of molecular chaperones in clathrin mediated vesicular trafficking.

Sousa R., Lafer E.M.,

Front Mol Biosci 2:26-26(2015)

Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival.

Farooqui M., Bohrer L.R., Brady N.J., Chuntova P., Kemp S.E., Wardwell C.T., Nelson A.C., Schwertfeger K.L.,

Mol Cancer 14:138-138(2015)

Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.

Hu Z., Hu Y., Liu X., Xi R., Zhang A., Liu D., Xie Q., Chen L.,

Oncotarget 6:31628-31639(2015)

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.

Suzawa K., Toyooka S., Sakaguchi M., Morita M., Yamamoto H., Tomida S., Ohtsuka T., Watanabe M., Hashida S., Maki Y., Soh J., Asano H., Tsukuda K., Miyoshi S.,

Cancer Sci 107:45-52(2016)

Epiregulin Recognition Mechanisms by Anti-epiregulin Antibody 9E5: STRUCTURAL, FUNCTIONAL, AND MOLECULAR DYNAMICS SIMULATION ANALYSES.

Kado Y., Mizohata E., Nagatoishi S., Iijima M., Shinoda K., Miyafusa T., Nakayama T., Yoshizumi T., Sugiyama A., Kawamura T., Lee Y.H., Matsumura H., Doi H., Fujitani H., Kodama T., Shibasaki Y., Tsumoto K., Inoue T.,

J Biol Chem 291:2319-2330(2016)

Autocrine epiregulin activates EGFR pathway for lung metastasis via EMT in salivary adenoid cystic carcinoma.

Liu S., Ye D., Xu D., Liao Y., Zhang L., Liu L., Yu W., Wang Y., He Y., Hu J., Guo W., Wang T., Sun B., Song H., Yin H., Liu J., Wu Y., Zhu H., Zhang Z.,

Oncotarget 7:25251-25263(2016)

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.

Qu X., Sandmann T., Frierson H. Jr., Fu L., Fuentes E., Walter K., Okrah K., Rumpel C., Moskaluk C., Lu S., Wang Y., Bourgon R., Penuel E., Pirzkall A., Amler L., Lackner M.R., Tabernero J., Hampton G.M., Kabbarah O.,

Oncogene 35:6403-6415(2016)

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.

Lee M.S., McGuffey E.J., Morris J.S., Manyam G., Baladandayuthapani V., Wei W., Morris V.K., Overman M.J., Maru D.M., Jiang Z.Q., Hamilton S.R., Kopetz S.,

Br J Cancer 114:1352-1361(2016)

Resveratrol regulates gene transcription via activation of stimulus-responsive transcription factors.

Thiel G., Rossler O.G.,

Pharmacol Res 117:166-176(2017)

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Hanker A.B., Brewer M.R., Sheehan J.H., Koch J.P., Sliwoski G.R., Nagy R., Lanman R., Berger M.F., Hyman D.M., Solit D.B., He J., Miller V., Cutler R.E. Jr., Lalani A.S., Cross D., Lovly C.M., Meiler J., Arteaga C.L.,

Cancer Discov 7:575-585(2017)

Potential Involvement of the Epidermal Growth Factor Receptor Ligand Epiregulin and Matrix Metalloproteinase-1 in Pathogenesis of Chronic Rhinosinusitis.

Homma T., Kato A., Sakashita M., Takabayashi T., Norton J.E., Suh L.A., Carter R.G., Harris K.E., Peters A.T., Grammer L.C., Min J.Y., Shintani-Smith S., Tan B.K., Welch K., Conley D.B., Kern R.C., Schleimer R.P.,

Am J Respir Cell Mol Biol 57:334-345(2017)

Integrin alpha6beta4 Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation.

Carpenter B.L., Liu J., Qi L., Wang C., O'Connor K.L.,

Sci Rep 7:6174-6174(2017)

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.

Freed D.M., Bessman N.J., Kiyatkin A., Salazar-Cavazos E., Byrne P.O., Moore J.O., Valley C.C., Ferguson K.M., Leahy D.J., Lidke D.S., Lemmon M.A.,

Cell 171:683-695.e18(2017)

Epiregulin (EREG) is upregulated through an IL-1beta autocrine loop in Caco-2 epithelial cells with reduced CFTR function.

Massip-Copiz M., Clauzure M., Valdivieso A.G., Santa-Coloma T.A.,

J Cell Biochem 119:2911-2922(2018)

Proline-Rich Protein Tyrosine Kinase 2 in Inflammation and Cancer.

Zhu X., Bao Y., Guo Y., Yang W.,

Cancers (Basel) 10:0-0(2018)

Epiregulin promotes the migration and chemotaxis ability of adipose-derived mesenchymal stem cells via mitogen-activated protein kinase signaling pathways.

Cao Y., Wang L., Yang H., Lin X., Li G., Han N., Du J., Fan Z.,

J Cell Biochem 119:8450-8459(2018)

Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer.

Bormann F., Stinzing S., Tierling S., Morkel M., Markelova M.R., Walter J., Weichert W., Rossner F., Kuhn N., Perner J., Dietz J., Ispasanie S., Dietel M., Schafer R., Heinemann V., Sers C.,

Int J Cancer 144:569-581(2019)

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco E., Javier Carmona F., Razavi P., Won H.H., Cai Y., Rossi V., Chan C., Cownie J., Soong J., Toska E., Shifman S.G., Sarotto I., Savas P., Wick M.J., Papadopoulos K.P., Moriarty A., Cutler R.E. Jr., Avogadri-Connors F., Scaltriti M.,

Sci Signal 11:0-0(2018)

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.

Croessmann S., Formisano L., Kinch L.N., Gonzalez-Ericsson P.I., Sudhan D.R., Nagy R.J., Mathew A., Bernicker E.H., Cristofanilli M., He J., Cutler R.E. Jr., Lalani A.S., Miller V.A., Lanman R.B., Grishin N.V., Arteaga C.L.,

Clin Cancer Res 25:277-289(2019)

Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.

Pahuja K.B., Nguyen T.T., Jaiswal B.S., Prabhash K., Thaker T.M., Senger K., Chaudhuri S., Kljavin N.M., Antony A., Phalke S., Kumar P., Mravic M., Stawiski E.W., Vargas D., Durinck S., Gupta R., Khanna-Gupta A., Trabucco S.E., Seshagiri S.,

Cancer Cell 34:792-806.e5(2018)

E2F7, EREG, miR-451a and miR-106b-5p are associated with the cervical cancer development.

Zong S., Liu X., Zhou N., Yue Y.,

Arch Gynecol Obstet 299:1089-1098(2019)

Elevated epiregulin expression predicts poor prognosis in gastric cancer.

Xia Q., Zhou Y., Yong H., Wang X., Zhao W., Ding G., Zhu J., Li X., Feng Z., Wang B.,

Pathol Res Pract 215:873-879(2019)

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations.

Ogoshi Y., Shien K., Yoshioka T., Torigoe H., Sato H., Sakaguchi M., Tomida S., Namba K., Kurihara E., Takahashi Y., Suzawa K., Yamamoto H., Soh J., Toyooka S.,

Oncol Lett 17:2729-2736(2019)

The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells.

He M., Jin Q., Chen C., Liu Y., Ye X., Jiang Y., Ji F., Qian H., Gan D., Yue S., Zhu W., Chen T.,

Oncogene 38:5551-5565(2019)

Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway.

Wang Y., Jing Y., Ding L., Zhang X., Song Y., Chen S., Zhao X., Huang X., Pu Y., Wang Z., Ni Y., Hu Q.,

J Exp Clin Cancer Res 38:274-274(2019)

Amphiregulin/epiregulin mRNA Expression and Primary Tumor Location in Colorectal Cancer.

Kuramochi H., Nakajima G.O., Hayashi K., Araida T., Yamamoto M.,

Anticancer Res 39:4729-4736(2019)

High EREG Expression Is Predictive of Better Outcomes in Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.

Lin C.Y., Hsieh P.L., Chou C.L., Yang C.C., Lee S.W., Tian Y.F., Shiue Y.L., Li W.S.,

Oncology 98:549-557(2020)

An enzyme that removes clathrin coats: purification of an uncoating ATPase.

Schlossman D.M., Schmid S.L., Braell W.A., Rothman J.E.,

J Cell Biol 99:723-733(1984)

Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase.

Ricci A., Lanfrancone L., Chiari R., Belardo G., Pertica C., Natali P.G., Pelicci P.G., Segatto O.,

Oncogene 11:1519-1529(1995)

Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor.

Batzer A.G., Rotin D., Urena J.M., Skolnik E.Y., Schlessinger J.,

Mol Cell Biol 14:5192-5201(1994)

Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells.

Okutani T., Okabayashi Y., Kido Y., Sugimoto Y., Sakaguchi K., Matuoka K., Takenawa T., Kasuga M.,

J Biol Chem 269:31310-31314(1994)

Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2.

VanderKuur J., Allevato G., Billestrup N., Norstedt G., Carter-Su C.,

J Biol Chem 270:7587-7593(1995)

The phosphotyrosine interaction domain of SHC recognizes tyrosine-phosphorylated NPXY motif.

Songyang Z., Margolis B., Chaudhuri M., Shoelson S.E., Cantley L.C.,

J Biol Chem 270:14863-14866(1995)

The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor.

Batzer A.G., Blaikie P., Nelson K., Schlessinger J., Margolis B.,

Mol Cell Biol 15:4403-4409(1995)

Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.

Wallasch C., Weiss F.U., Niederfellner G., Jallal B., Issing W., Ullrich A.,

EMBO J 14:4267-4275(1995)

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.

Riese D.J., van Raaij T.M., Plowman G.D., Andrews G.C., Stern D.F.,

Mol Cell Biol 15:5770-5776(1995)

Journey to the surface of the cell: Fos regulation and the SRE.

Treisman R.,

EMBO J 14:4905-4913(1995)

Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation.

Galisteo M.L., Dikic I., Batzer A.G., Langdon W.Y., Schlessinger J.,

J. Biol. Chem. 270:20242-20245(1995)

Dynamin self-assembles into rings suggesting a mechanism for coated vesicle budding.

Hinshaw J.E., Schmid S.L.,

Nature 374:190-192(1995)

ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation.

Gille H., Kortenjann M., Thomae O., Moomaw C., Slaughter C., Cobb M.H., Shaw P.E.,

EMBO J. 14:951-962(1995)

ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms.

Tzahar E., Levkowitz G., Karunagaran D., Yi L., Peles E., Lavi S., Chang D., Liu N., Yayon A., Wen D.,

J Biol Chem 269:25226-25233(1994)

Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera.

Prigent S.A., Gullick W.J.,

EMBO J 13:2831-2841(1994)

Potent SHC tyrosine phosphorylation by epidermal growth factor at low receptor density or in the absence of receptor autophosphorylation sites.

Soler C., Alvarez C.V., Beguinot L., Carpenter G.,

Oncogene 9:2207-2215(1994)

Shc products are substrates of erbB-2 kinase.

Segatto O., Pelicci G., Giuli S., Digiesi G., Di Fiore P.P., McGlade J., Pawson T., Pelicci P.G.,

Oncogene 8:2105-2112(1993)

The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain.

Marais R., Wynne J., Treisman R.,

Cell 73:381-393(1993)

Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2.

Chardin P., Camonis J.H., Gale N.W., van Aelst L., Wigler M.H., Bar-Sagi D.,

Science 260:1338-1343(1993)

Role of auxilin in uncoating clathrin-coated vesicles.

Ungewickell E., Ungewickell H., Holstein S.E., Lindner R., Prasad K., Barouch W., Martin B., Greene L.E., Eisenberg E.,

Nature 378:632-635(1995)

Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu.

Xie Y., Pendergast A.M., Hung M.C.,

J Biol Chem 270:30717-30724(1995)

A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals.

David C., McPherson P.S., Mundigl O., de Camilli P.,

Proc Natl Acad Sci U S A 93:331-335(1996)

ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.

Karunagaran D., Tzahar E., Beerli R.R., Chen X., Graus-Porta D., Ratzkin B.J., Seger R., Hynes N.E., Yarden Y.,

EMBO J 15:254-264(1996)

HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers.

Cohen B.D., Green J.M., Foy L., Fell H.P.,

J. Biol. Chem. 271:4813-4818(1996)

Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells.

Sepp-Lorenzino L., Eberhard I., Ma Z., Cho C., Serve H., Liu F., Rosen N., Lupu R.,

Oncogene 12:1679-1687(1996)

Activation of epidermal growth factor receptor by epidermal growth factor.

Sherrill J.M., Kyte J.,

Biochemistry 35:5705-5718(1996)

Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction.

Wymann M.P., Bulgarelli-Leva G., Zvelebil M.J., Pirola L., Vanhaesebroeck B., Waterfield M.D., Panayotou G.,

Mol Cell Biol 16:1722-1733(1996)

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., Lavi S., Seger R., Ratzkin B.J., Sela M., Yarden Y.,

EMBO J 15:2452-2467(1996)

In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c-src: identification of phosphorylation sites and c-src SH2 domain binding sites.

Lombardo C.R., Consler T.G., Kassel D.B.,

Biochemistry 34:16456-16466(1995)

Synaptic vesicle endocytosis impaired by disruption of dynamin-SH3 domain interactions.

Shupliakov O., Low P., Grabs D., Gad H., Chen H., David C., Takei K., De Camilli P., Brodin L.,

Science 276:259-263(1997)

Auxilin-induced interaction of the molecular chaperone Hsc70 with clathrin baskets.

Barouch W., Prasad K., Greene L., Eisenberg E.,

Biochemistry 36:4303-4308(1997)

Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation.

Elenius K., Paul S., Allison G., Sun J., Klagsbrun M.,

EMBO J. 16:1268-1278(1997)

Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.

Carraway K.L. III, Weber J.L., Unger M.J., Ledesma J., Yu N., Gassmann M., Lai C.,

Nature 387:512-516(1997)

Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4.

Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Hillan K., Crowley C., Brush J., Godowski P.J.,

Proc. Natl. Acad. Sci. U.S.A. 94:9562-9567(1997)

Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor.

Holgado-Madruga M., Moscatello D.K., Emlet D.R., Dieterich R., Wong A.J.,

Proc Natl Acad Sci U S A 94:12419-12424(1997)

A novel role for Rab5-GDI in ligand sequestration into clathrin-coated pits.

McLauchlan H., Newell J., Morrice N., Osborne A., West M., Smythe E.,

Curr Biol 8:34-45(1998)

Synaptojanin 1: localization on coated endocytic intermediates in nerve terminals and interaction of its 170 kDa isoform with Eps15.

Haffner C., Takei K., Chen H., Ringstad N., Hudson A., Butler M.H., Salcini A.E., Di Fiore P.P., De Camilli P.,

FEBS Lett. 419:175-180(1997)

Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation.

Zrihan-Licht S., Deng B., Yarden Y., McShan G., Keydar I., Avraham H.,

J Biol Chem 273:4065-4072(1998)

Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells.

Sakaguchi K., Okabayashi Y., Kido Y., Kimura S., Matsumura Y., Inushima K., Kasuga M.,

Mol Endocrinol 12:536-543(1998)

Synonyms

Description

KO Status

Drug Information

TGF-alpha/epiregulin monoclonal antibody